EyePoint Pharmaceuticals, Inc.
For the period ended Jun 30, 2025. Filed Aug 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 7, 2025
EYPT$0.40+11.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows –
(In thousands)
| Six Months Ended | ||
|---|---|---|
| June 30, | ||
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(104,621) | $(60,110) |
| Adjustments to reconcile net loss to cash flows used in operating activities: | ||
| Depreciation of property and equipment | 1,035 | 665 |
| Amortization of debt discount and premium and discount on available-for-sale marketable securities | (2,934) | (2,267) |
| Stock-based compensation | 14,696 | 21,394 |
| Deferred income tax | (90) | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable and other current assets | 3,248 | (1,168) |
| Other assets | (62) | — |
| Inventory | (373) | 233 |
| Accounts payable and accrued expenses | 1,504 | 3,636 |
| Right-of-use assets and operating lease liabilities | 543 | 539 |
| Deferred revenue | (28,637) | (14,271) |
| Other noncurrent liabilities | (18) | — |
| Net cash (used in) provided by operating activities | (115,709) | (51,349) |
| Cash flows from investing activities: | ||
| Purchases of marketable securities | (93,368) | (184,995) |
| Sales and maturities of marketable securities | 182,725 | 47,500 |
| Purchases of property and equipment | (1,496) | (2,094) |
| Net cash (used in) provided by investing activities | 87,861 | (139,589) |
| Cash flows from financing activities: | ||
| Payment of equity issue costs | (291) | (307) |
| Net settlement of stock units to satisfy statutory tax withholding | (1,237) | (4,434) |
| Proceeds from exercise of stock options and employee stock purchase plan | 866 | 5,185 |
| Principal payments on finance lease obligations | (51) | — |
| Net cash (used in) provided by financing activities | (713) | 444 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (28,561) | (190,494) |
| Cash, cash equivalents and restricted cash at beginning of period | 99,854 | 281,413 |
| Cash, cash equivalents and restricted cash at end of period | $71,293 | $90,919 |
| Reconciliation of cash, cash equivalents and restricted cash to the condensed consolidated balance sheets: | ||
| Cash and cash equivalents | $71,143 | $90,769 |
| Restricted cash | 150 | 150 |
| Total cash, cash equivalents and restricted cash at end of period | $71,293 | $90,919 |
| Supplemental disclosure of non-cash investing and financing activities: | ||
| Lease liability arising from obtaining right-of-use assets | $903 | $17,656 |
| Property and equipment additions in accounts payable and accrued expenses | $43 | $220 |
| Stock issuance costs in accounts payable and accrued expenses | $20 | $— |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.